Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.

ESC Heart Fail · 2018 · PMC5880673 · PMID 29476612

Europe PMC DOI

hedged sentence

0.0565

closest p · 1.1× alpha

0.0565

boldest claim

The sentences

showed a trendP = 0.0565so close (0.05 < p ≤ 0.1)

Similarly, copeptin showed a trend ( P = 0.0565) towards a 19% improvement of net reclassification for patients at the highest risk of 90 day mortality or rehospitalization (95% confidence interval [−0.5, 39.1]).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.